We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Astex Achieves Milestones in GSK Collaboration
News

Astex Achieves Milestones in GSK Collaboration

Astex Achieves Milestones in GSK Collaboration
News

Astex Achieves Milestones in GSK Collaboration

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Astex Achieves Milestones in GSK Collaboration"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Astex Therapeutics, has announced that it has achieved multiple early milestones in its fragment-based drug discovery collaboration with GlaxoSmithKline which commenced in November 2009. Total milestone payments received under the collaboration have now reached £5.9 million.

The milestones relate to the application of Astex’s Pyramid™ fragment based screening platform, against a number of molecular targets of interest to GSK.

Following the identification of validated fragment hits, the joint project teams prioritize fragments to be taken into lead optimization with the intention of selecting clinical development candidates for further development by GSK.

Commenting on the achievement of the early milestones, Dr Harren Jhoti, Astex’s Chief Executive Officer said, “We are delighted to have achieved these initial milestones within 18 months of beginning our collaboration with GSK. This achievement is testament, not only to the power of Astex’s technology to rapidly deliver novel chemical start points against challenging disease targets, but is also a reflection of how well the Astex-GSK joint project teams are working together in the collaboration.

Advertisement